Status:
COMPLETED
Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.
Eligibility Criteria
Inclusion
- sitting office diastolic blood pressure between 90 and 109 mmHg
- office systolic blood pressure between 140 and 179 mmHg
- mean day-time diastolic 24-h ABPM blood pressure \>= 85 mmHg inclusive at baseline
Exclusion
- known secondary hypertension
- decompensated congestive heart failure
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00160212
Start Date
December 1 2004
Last Update
January 30 2009
Active Locations (130)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 705
Bracken Ridge, Australia
2
Site 706
Caboolture, Australia
3
Site 700
Inala, Australia
4
Site 701
Kippa-Ring, Australia